Role of mast cells and pro-inflammatory mediators on the intestinal secretion induced by cholera toxin.
Recent data suggest that diarrhea caused by Vibrio cholerae involves a pro-inflammatory mediators release, such as cytokines, prostaglandin and nitric oxide. The aim of this study was to investigate the role of mast cells and their mediators in the intestinal secretion induced by cholera toxin. We examined the dose responses, time course and role of mast cells and pro-inflammatory mediators in cholera toxin intestinal secretory response, in vivo. Cholera toxin caused a dose-dependent secretion, in ligated small intestine loops, at 18 h. Rats treated with 48/80 compound or ketotifen had a significant decrease in the intestinal secretory response. Cholera toxin secretion was significantly reduced by an unspecific histamine/serotonin receptor antagonist, histamine receptor antagonist, phospholipase A2 and cyclooxygenase inhibitors, platelet-activating factor (PAF) receptor antagonists and TNF-alpha synthesis blockers. On the other hand, pretreatment with a specific serotonin receptor antagonist and lipoxygenase inhibitors failed to block this effect. Analysis of the intestinal fluid from rats injected with cholera toxin, revealed that cholera toxin induces the release of IL-1beta and TNF-alpha into fluid. The data suggest that, at least in part, mast cells are involved in cholera toxin-induced secretion, as well as point to the importance of histamine, prostaglandins, PAF, IL-1beta and TNF-alpha in this process.
Rocha
Marcos F G
MF
Faculty of Veterinary, State University of Ceará, Fortaleza, CE, Brazil. rocha@rapix.com.br
Aguiar
José E P
JE
Sidrim
José J C
JJ
Costa
Raimundo B
RB
Feitosa
Regina F G
RF
Ribeiro
Ronaldo A
RA
Lima
Aldo A M
AA
D000818:Animals; D002772:Cholera Toxin / Q000037:antagonists & inhibitors / Q000633:toxicity*; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D006633:Histamine Antagonists / Q000494:pharmacology; D007249:Inflammation / Q000378:metabolism; D007375:Interleukin-1 / Q000378:metabolism; D007421:Intestine, Small / Q000187:drug effects* / Q000378:metabolism*; D008407:Mast Cells / Q000378:metabolism*; D010741:Phospholipases A / Q000037:antagonists & inhibitors / Q000494:pharmacology; D054467:Phospholipases A2; D010980:Platelet Membrane Glycoproteins / Q000037:antagonists & inhibitors / Q000494:pharmacology; D051381:Rats; D011956:Receptors, Cell Surface / Q000037:antagonists & inhibitors; D043562:Receptors, G-Protein-Coupled; D012702:Serotonin Antagonists / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000378:metabolism; D014734:Vibrio cholerae
D016861:Cyclooxygenase Inhibitors; D006633:Histamine Antagonists; D007375:Interleukin-1; D010980:Platelet Membrane Glycoproteins; D011956:Receptors, Cell Surface; D043562:Receptors, G-Protein-Coupled; D012702:Serotonin Antagonists; D014409:Tumor Necrosis Factor-alpha; C039351:platelet activating factor receptor; D002772:Cholera Toxin; D010741:Phospholipases A; D054467:Phospholipases A2